% Expired Patents = 40.0

EPO Patents = 3

Forward Citations = 5

Loading Chart...

2 inventors (with patents filed for the assignee):

Adonia E Papathanassiu (5 out of 12 patents)

Adonia Papathanassiu (0 patent)

5 patents: Sort by Forward Citations

1. 12060310 - Compositions and methods of using itaconic acid derivatives (2024-08-13),

2. 10941109 - Compositions and methods of treatment using a BCAT1 inhibitor (2021-03-09),

3. 9422224 - Methods of treatment using a BCAT1 inhibitor (2016-08-23),

4. 7381799 - Compositions and methods for inhibiting angiogenesis (2008-06-03),

5. 6528489 - Mycotoxin derivatives as antimitotic agents (2003-03-04),

Company Overview

Ergon Pharmaceuticals LLC is a leading pharmaceutical company dedicated to developing innovative and high-quality medications to improve patient health and wellbeing. With a focus on research and development, Ergon Pharmaceuticals is committed to delivering safe and effective pharmaceutical solutions for a variety of medical conditions. Our team of experts work tirelessly to discover and bring to market new treatments that make a meaningful difference in people's lives.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

5 Patents

#27 in Silver Spring, MD

#749 in Maryland

#51,570 in US

Silver Spring, MD, United States of America

Ergon Pharmaceuticals LLC

Forward Citations = 5

2 inventors:

Adonia E Papathanassiu (5 out of 12 patents)

Adonia Papathanassiu (0 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ergon Pharmaceuticals LLC. Retrieved from https://idiyas.com/company/ergon-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

3 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]